1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review

I.B Riaz,S.A.A Naqvi,H He,N Asghar,R Siddiqi,K.Z.R Khakwani,H Liu,S.A Hussain,P Singh,M Murad,A.H Bryce

doi:10.1016/j.annonc.2022.07.1903

1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review

I.B Riaz, S.A.A Naqvi + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1903

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: University of Arizona, Dow University of Health Sciences, University of Sheffield

#Metastatic Castration Sensitive Prostate Cancer #Comparative Effectiveness Of Treatments + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Results from recent trials (PEACE-1, and ARASENS), the disease heterogeneity in mCSPC and lack of direct comparisons between triplets and novel hormonal therapy (NHT) doublets prompted us to assess the comparative effectiveness of contemporary treatments accounting for volume of disease.

Full Text